Comparison

Liraglutide vs. Lixisenatide

Two peptides side-by-side — identity, evidence base, legal status and known adverse events.

Identity

Mechanism of action

Liraglutide

Liraglutide is a synthetic GLP-1 analog with 97% sequence identity to human GLP-1. A fatty-acid side chain (C16) on Lys-26 reversibly binds serum albumin and protects against DPP-4 degradation. GLP-1 receptor activation glucose-dependently stimulates insulin secretion, inhibits glucagon secretion, delays gastric emptying and modulates central satiety.

Lixisenatide

Lixisenatide is a 44-amino-acid peptide based on exendin-4 (see exenatide) with six additional lysine residues at the C-terminus. This modification increases stability against DPP-4 degradation. The short half-life (~3 hours) and plasma peak around mealtime explain the predominantly prandial effect — stronger postprandial glucose action, weaker fasting glucose effect than weekly GLP-1 RAs.

Evidence base

Highest evidence

Human RCT

Studies

of which in humans

Effects recorded

Open conflicts

Documented adverse events

Legal status

Country	Liraglutide	Lixisenatide
Germany	Prescription	Prescription
JP	—	Prescription
United States	Prescription	Unapproved

Full entries

Frequently asked questions

What is the difference between Liraglutide and Lixisenatide?: Liraglutide is classified as "Metabolic", while Lixisenatide is classified as "Metabolic". Liraglutide: GLP-1 receptor agonist with a half-life of about 13 hours. The first daily (not weekly) modern GLP-1 RA — approved as Victoza for type 2 diabetes (2010) and Saxenda for obesity (2014). Lixisenatide: Synthetic exendin-4 analog with a C-terminal lysine extension. Prandial GLP-1 RA focused on postprandial glucose. FDA-approved 2016 as Adlyxin; EMA-approved 2013 as Lyxumia. Sanofi discontinued US distribution in 2023. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, Liraglutide or Lixisenatide?: The highest available evidence level is "Human RCT" for Liraglutide and "Human RCT" for Lixisenatide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of Liraglutide and Lixisenatide in Germany and the United States?: Germany: Liraglutide — Prescription, Lixisenatide — Prescription. United States: Liraglutide — Prescription, Lixisenatide — Unapproved. These are factual summaries with source and review date on the individual pages.

Country

Liraglutide

Lixisenatide

Germany

Prescription

—

Prescription

United States

Prescription

Unapproved

Frequently asked questions

What is the difference between Liraglutide and Lixisenatide?

Liraglutide is classified as "Metabolic", while Lixisenatide is classified as "Metabolic". Liraglutide: GLP-1 receptor agonist with a half-life of about 13 hours. The first daily (not weekly) modern GLP-1 RA — approved as Victoza for type 2 diabetes (2010) and Saxenda for obesity (2014). Lixisenatide: Synthetic exendin-4 analog with a C-terminal lysine extension. Prandial GLP-1 RA focused on postprandial glucose. FDA-approved 2016 as Adlyxin; EMA-approved 2013 as Lyxumia. Sanofi discontinued US distribution in 2023. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, Liraglutide or Lixisenatide?

The highest available evidence level is "Human RCT" for Liraglutide and "Human RCT" for Lixisenatide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of Liraglutide and Lixisenatide in Germany and the United States?

Germany: Liraglutide — Prescription, Lixisenatide — Prescription. United States: Liraglutide — Prescription, Lixisenatide — Unapproved. These are factual summaries with source and review date on the individual pages.